Every story from Tele Launched, newest first: FDA, DEA and CMS actions, compounding, peptides, AI and the business of virtual care.
Cash-pay clinics are putting peptide menus on the same pages as memberships and telehealth booking. Operators and counsel still have to decide whether that copy is a medical-practice claim, a drug advertisement, or both.
A staff note on launch transparency: where AI may assist drafting, where humans stay accountable, and what we will not publish.
Branded GLP-1 injections are easier to obtain than they were during the shortage. Direct-to-consumer telehealth sites that built weight-loss programs on compounded versions are changing menus, prices, and pharmacy-partner lists in public.
FDA's post-shortage compounding reminders and "essentially a copy" framing are reshaping playbooks for 503A pharmacies, 503B facilities, and virtual prescribing programs.